Objective:

To evaluate the comparative efficacy and safety of Oral Chinese Patent Medicines (OCPMs) combined with conventional Western therapy in patients with coronary heart disease (CHD) complicated by diabetes mellitus (DM), highlighting the significance of this evaluation in improving treatment outcomes.

Key Findings:

• Shexiang Baoxin Pills showed optimal efficacy in reducing triglycerides and improving HDL-C, which is crucial for cardiovascular health.
• Tongxinluo Capsules achieved the best outcomes in reducing 2-h postprandial blood glucose, important for diabetes management.
• Yindan Xinnaotong Soft Capsules enhanced left ventricular ejection fraction and reduced blood viscosity, indicating improved cardiac function.
• Guanxinning Tablets effectively lowered glycated hemoglobin, a key marker for diabetes control.
• Jinlida Granules reduced fasting blood glucose and LDL-C, both critical for managing diabetes and cardiovascular risk.
• Liuwei Dihuang Pills reduced the incidence of major adverse cardiovascular events, highlighting their protective role.
• Yangxinshi Tablets significantly decreased NT-proBNP levels, suggesting improved heart failure outcomes.
• Danzhi Jiangtang Capsules achieved the best outcomes in reducing total cholesterol, important for cardiovascular health.

Interpretation:

OCPMs combined with conventional therapy provide multidimensional benefits for patients with CHD and DM, with implications for clinical practice, but results should be interpreted cautiously due to study heterogeneity and quality.

Limitations:

• Heterogeneity among included studies may affect the reliability of results.
• Variable quality of the studies assessed could introduce bias in the findings.

Conclusion:

The findings suggest that OCPMs can be beneficial as adjunctive therapy in managing CHD complicated by diabetes, warranting further high-quality, large-scale multicenter RCTs for confirmation to enhance treatment strategies.